Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
The new sharewise is here Clearer, faster, with a light and a dark view — and everything you already know. Try it now
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Get an introduction to all features of this page

Cytokinetics Inc. Stock

Price
Target price
€64.50

€64.50

1.290%
0.82
1.290%
€81.13
 
15:25 / Tradegate WKN: A1W1KK / Symbol: CYTK / Name: Cytokinetics / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
Buy
None
Sell
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Pros and Cons of Cytokinetics Inc. in the next few years
Wizard

Cytokinetics Inc. Stock

Cytokinetics Inc. gained 1.290% today.
The stock is an absolute favorite of our community with 47 Buy predictions and no Sell predictions.
As a result the target price of 81 € shows a positive potential of 25.58% compared to the current price of 64.5 € for Cytokinetics Inc..
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Cytokinetics Inc. stock. Negative votes have not been in the majority for any criteria for this stock
What does Cytokinetics do?

Pros and Cons of Cytokinetics Inc. in the next few years

Pros
?
S********** s********
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Cons
?
C******** o* t** e**********
?
M***** P*******
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Your Opinion
Legal notice

Performance of Cytokinetics Inc. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Cytokinetics Inc. 1.290% -10.031% -11.825% 101.519% 19.028% 110.861% 129.065%
Heron Therapeutics Inc. 2.340% -32.607% -20.601% -75.641% -73.914% -80.497% -96.899%
Evolus Inc -0.400% 27.435% 22.133% 31.811% 28.183% -21.506% -21.506%
Rhythm Pharmaceuticals -0.990% 6.878% 7.447% 24.691% 8.021% 313.934% 763.248%

Comments

Cytokinetics (CYTK) had its "buy" rating reaffirmed by HC Wainwright.
Ratings data for CYTK provided by MarketBeat
Show more

HC Wainwright 
0
Report Share
15:00 Buy 0.00%
Prediction Buy
Perf. (%) 0.12%
Target price 89.383
Change
Ends at 13.08.27

Cytokinetics (CYTK) had its price target raised by JPMorgan Chase & Co. from $97.00 to $103.00. They now have an "overweight" rating on the stock.
Ratings data for CYTK provided by MarketBeat
Show more

JPMorgan Chase & Co. 
0
Report Share
13.08.26

Cytokinetics (CYTK) had its "overweight" rating reaffirmed by Barclays PLC.
Ratings data for CYTK provided by MarketBeat
Show more

Barclays PLC 
0
Report Share
13.08.26 Buy -1.86%
Show more
Not a member yet? Sign up for free!

News

Cytokinetics Q2 Earnings Call HighlightsPhoto, wide shot, wide-angle lens, soft focus, Clinical research organization, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Hiroshi Sugimoto: https://oaidalleapiprodscus.blob.core.windows.net/private/org-IbuNdCATsFaPOITjFOv2kJh3/user-AXaxqjBUW45D8BadJEo9mUpW/img-d5U47McddROtnUwv1JIaZvc2.png?st=2023-05-04T16%3A11%3A57Z&se=2023-05-04T18%3A11%3A57Z&sp=r&sv=2021-08-06&sr=b&rscd=inline&rsct=image/png&skoid=6aaadede-4fb3-4698-a8f6-684d7786b067&sktid=a48cca56-e6da-484e-a814-9c849652bcb3&skt=2023-05-04T16%3A04%3A37Z&ske=2023-05-05T16%3A04%3A37Z&sks=b&skv=2021-08-06&sig=KvGLXJQj4L2uYw31IYBsPpHX4telRq/7natMW2uEF58%3D
Cytokinetics Q2 Earnings Call Highlights

Key Points

MarketBeat 
0 07.08.26
What This Cytokinetics Insider Sale Might Mean With the Stock Up 110%Photo, wide shot, wide-angle lens, soft focus, Clinical research organization, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Hiroshi Sugimoto: https://oaidalleapiprodscus.blob.core.windows.net/private/org-IbuNdCATsFaPOITjFOv2kJh3/user-AXaxqjBUW45D8BadJEo9mUpW/img-d5U47McddROtnUwv1JIaZvc2.png?st=2023-05-04T16%3A11%3A57Z&se=2023-05-04T18%3A11%3A57Z&sp=r&sv=2021-08-06&sr=b&rscd=inline&rsct=image/png&skoid=6aaadede-4fb3-4698-a8f6-684d7786b067&sktid=a48cca56-e6da-484e-a814-9c849652bcb3&skt=2023-05-04T16%3A04%3A37Z&ske=2023-05-05T16%3A04%3A37Z&sks=b&skv=2021-08-06&sig=KvGLXJQj4L2uYw31IYBsPpHX4telRq/7natMW2uEF58%3D
What This Cytokinetics Insider Sale Might Mean With the Stock Up 110%

Robert I. Blum, president & CEO of Cytokinetics, Incorporated (NASDAQ:CYTK), reported a sale of 7,500 shares of common stock on July 13, 2026, according to an SEC Form 4 filing.

Transaction value

TheMotleyFool 
0 14.07.26
Cytokinetics Says MYKORZO Launch Tops Expectations as HCM Data Draws PraisePhoto, wide shot, wide-angle lens, soft focus, Biotech company, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Hiroshi Sugimoto: https://oaidalleapiprodscus.blob.core.windows.net/private/org-IbuNdCATsFaPOITjFOv2kJh3/user-AXaxqjBUW45D8BadJEo9mUpW/img-pKgbwxVSbyTCu0UzPNe8NL8D.png?st=2023-05-04T16%3A02%3A58Z&se=2023-05-04T18%3A02%3A58Z&sp=r&sv=2021-08-06&sr=b&rscd=inline&rsct=image/png&skoid=6aaadede-4fb3-4698-a8f6-684d7786b067&sktid=a48cca56-e6da-484e-a814-9c849652bcb3&skt=2023-05-04T12%3A13%3A51Z&ske=2023-05-05T12%3A13%3A51Z&sks=b&skv=2021-08-06&sig=%2BhYssNp3W0HiZMxCV64XVELyP8stYUjFhgUVfPrTLyg%3D
Cytokinetics Says MYKORZO Launch Tops Expectations as HCM Data Draws Praise

Key Points

MarketBeat 
0 22.05.26